Amgen on Monday, February 24, announced the opening of Amgen India, its new technology and innovation site in Hyderabad.
The company plans to invest USD 200 million through 2025, with additional sustained investments planned over the coming years, an official news release stated.
The site will accelerate Amgen’s digital capabilities through artificial intelligence and data science to further advance its pipeline of medicines, while creating significant opportunities for local talent.
Amgen India is located in HITEC City, occupying approximately 524,000 square feet in RMZ Tower 110 of Spire and Tower 20 of Nexity.
Robert A. Bradway, chairman and chief executive officer at Amgen, was joined by Telangana Chief Minister Anumula Revanth Reddy, and D. Sridhar Babu, Minister of IT, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana, at the site opening on Monday.
Speaking at the event, Reddy said, “I welcome Amgen to our vibrant city, as they work toward making a difference in patients’ lives around the world. We look forward to working with global leaders such as Amgen to strengthen Hyderabad’s position as a biotech hub.”
Bradway said, “The opening of Amgen India marks a significant milestone in our endeavour to leverage technology across our global network to better serve patients. We are grateful to the Government of Telangana for its partnership and are proud to join an ecosystem where life sciences and cutting-edge innovation can thrive.”
Under the leadership of the global organisation, Amgen India will play a pivotal role in advancing innovation by developing and deploying technology and life sciences solutions to accelerate Amgen’s digital capabilities worldwide.
“Amgen India is a reflection of our growth ambitions as well as an extension of our commitment to global health,” said Som Chattopadhyay, national executive for India at Amgen. “We are excited to contribute to the dynamic global biotech ecosystem from India and welcome the incredible talent pool the country offers.”
Naveen Gullapalli, managing director of Amgen India, emphasized the strategic value of the new site for the company’s global operations, stating: “Hyderabad is rapidly emerging as a global technology hub, and our new site is positioned at the heart of this landscape. Talent at Amgen India will drive global projects and initiatives, leveraging expertise across our global sites. Amgen India employees will bring bold, innovative thinking to help shape the future of global biotechnology from India.”
D. Sridhar Babu said, “With global leaders like Amgen choosing to invest here, we are poised to further enhance our capabilities, foster new opportunities, and set the stage for breakthrough innovations in both biotech and technology.”
Amgen has nearly 28,000 employees globally and a presence in approximately 100 countries and regions worldwide.
